A Case Study of MedSphere Stepless Adjustable Radiofrequency Ablation Electrode Needle

Radiofrequency Ablation (RFA) serves as one of the core technologies for minimally invasive interventional tumor therapy. Its efficacy and safety heavily rely on the performance of radiofrequency ablation electrode needles, the key consumable device. In recent years, domestic manufacturers represented by MedSphere (Shanghai) Co., Ltd. have broken import monopolies and driven the industry toward higher precision, safety and personalization via continuous technological innovation. The launch of its flagship product, the stepless adjustable radiofrequency ablation electrode needle, perfectly embodies this development trend.

1. Manufacturer Profile: Domestic Strength from Technology Introduction to Industrial Leadership

Founded in 2002, MedSphere is a professional medical device enterprise integrating R&D, production and sales. Initially built on the research foundation of its US parent company, the firm rapidly carried out localized upgrades tailored to domestic clinical demands and established robust independent R&D capabilities. Its core product portfolio covers radiofrequency generators (RFG) and matched electrode needles, focusing on minimally invasive treatment of solid tumors in liver, lung, thyroid and breast.The company has obtained NMPA registration certification and EU CE certification, and owns numerous domestic patents, ranking as a major player in China's radiofrequency ablation needle sector.

2. Core Product Technology Analysis: Stepless Adjustable Radiofrequency Ablation Electrode Needle

The stepless adjustable radiofrequency ablation electrode needle acquired Class III medical device registration approval from NMPA at the end of 2025, marking the latest technological achievement in precision ablation. Its core advantages are summarized as follows:

• Stepless adjustable working end for multi-lesion compatibilityConventional ablation needles feature fixed working lengths, requiring clinicians to switch specifications according to tumor sizes. The stepless adjustment technology enables real-time and continuous modification of exposed working length intraoperatively. One single needle adapts to diverse lesions, cutting down frequent instrument replacement and shortening operation duration. It also realizes conformal ablation matching tumor morphology, enhancing complete tumor eradication and protecting surrounding healthy tissues.
• Internal water circulation cooling systemHigh temperature during ablation triggers tissue carbonization around the needle tip. Carbonized layers raise electrical impedance, obstruct radiofrequency energy transmission and result in incomplete ablation or repeated surgical procedures. Equipped with an internal circulating water cooling structure, the electrode needle dissipates heat steadily to prevent carbonization, maintain stable energy output and form larger, uniform necrotic ablation zones.
• Precision manufacturing and ergonomic designThe triangular sharp needle tip allows direct percutaneous puncture without pre-incision, minimizing trauma and bleeding risks. The highly polished needle body avoids tissue adhesion and facilitates smooth needle withdrawal to prevent secondary injury. The ergonomic handle ensures comfortable manipulation, and clear scale markings on the cannula support accurate positioning under image guidance.

3. Product Portfolio and Market Competitiveness

Beyond the stepless adjustable electrode needle, MedSphere has developed a comprehensive product line catering to diversified clinical scenarios:

• Water-cooled needle series: Boasting the ultra-fine 19G needle with an outer diameter of approximately 1.07mm, it balances minimal invasion and maximal ablation area, ideal for tumors adjacent to vital organs and blood vessels.
• Non-magnetic claw-shaped needle: The first domestically developed non-magnetic radiofrequency electrode compatible with MRI guidance. Adopting fully non-magnetic materials, it resolves equipment compatibility issues under real-time MRI navigation and delivers superior therapeutic solutions for tumors in complex anatomical sites.
• Specialized electrodes: Customized devices for specific organs. Bronchoscopic radiofrequency ablation needles reach central lung cancer lesions inaccessible via conventional percutaneous puncture. Bone tumor electrodes adopt bipolar radiofrequency design to confine current loops within the electrode periphery, preventing neurological damage in spinal metastasis treatment.

4. Market Pattern and Industrial Influence

The global radiofrequency ablation needle market hosts numerous participants, including international giants such as Medtronic, Boston Scientific and Starmed, as well as leading domestic enterprises like MedSphere, Mianyang Lide Electronics and Weihai Hongyuan Medical. Classified by structure, products fall into single-electrode and multi-electrode types such as claw-shaped needles. Major clinical applications cover liver, lung, thyroid and breast tumor treatment.

Differentiated technological innovations secure MedSphere a distinctive competitive edge. Its products are widely adopted domestically and exported overseas with CE certification. Driven by provincial volume-based procurement policies, cost-effective domestic ablation needles are accelerating import substitution.Domestic manufacturers represented by MedSphere advance the high-quality development of China's minimally invasive tumor ablation industry through technological iteration including stepless adjustment, MRI compatibility and specialized design, as well as integrated equipment-consumable solutions, enabling more patients to access precise and minimally invasive therapies.